Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial.
Orvin K, Carrie D, Richardt G, Desmet W, Assali A, Werner G, Ikari Y, Fujii K, Goicolea J, Dangoisse V, Manari A, Saito S, Wijns W, Kornowski R. Orvin K, et al. Among authors: wijns w. Catheter Cardiovasc Interv. 2016 May;87(6):1092-100. doi: 10.1002/ccd.26150. Epub 2015 Aug 13. Catheter Cardiovasc Interv. 2016. PMID: 26268482 Clinical Trial.
Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial.
Wijns W, Verheye S, Manoharan G, Werner GS, Grube E, De Bruyne B, Koolen J, Hamm CW, Medina A, Bech JW, De Feyter PJ; CONVERTIBLE investigators. Wijns W, et al. Eur Heart J. 2005 Sep;26(18):1852-9. doi: 10.1093/eurheartj/ehi286. Epub 2005 May 11. Eur Heart J. 2005. PMID: 15888499 Clinical Trial.
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial.
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Fajadet J, et al. Among authors: wijns w. Circulation. 2006 Aug 22;114(8):798-806. doi: 10.1161/CIRCULATIONAHA.105.591206. Epub 2006 Aug 14. Circulation. 2006. PMID: 16908773 Clinical Trial.
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJ; ENDEAVOR II Trial Investigators. Sakurai R, et al. Among authors: wijns w. Am J Cardiol. 2007 Sep 1;100(5):818-23. doi: 10.1016/j.amjcard.2007.04.016. Epub 2007 Jun 14. Am J Cardiol. 2007. PMID: 17719326 Clinical Trial.
Drug-eluting stents: a critique.
Melikian N, Wijns W. Melikian N, et al. Among authors: wijns w. Heart. 2008 Feb;94(2):145-52. doi: 10.1136/hrt.2005.066993. Heart. 2008. PMID: 18195121 Review.
Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.
Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, Nedeljkovic M, Orlic D, Milosavljevic B, Topic D, Karanovic N, Wijns W; NOBORI CORE Investigators. Hamilos MI, et al. Among authors: wijns w. J Am Coll Cardiol. 2008 Jun 3;51(22):2123-9. doi: 10.1016/j.jacc.2007.12.059. J Am Coll Cardiol. 2008. PMID: 18510958 Free article. Clinical Trial.
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial.
Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Windecker S, et al. Among authors: wijns w. Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31. Lancet. 2008. PMID: 18765162 Clinical Trial.
The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic).
Verheye S, Sarno G, Müller R, Birkemeyer R, Vrints C, Jung W, Agostoni P, van Langenhove G, Haine S, Willems T, Haude M, Grube E, Wijns W. Verheye S, et al. Among authors: wijns w. EuroIntervention. 2009 Jun;5(2):233-8. doi: 10.4244/eijv5i2a36. EuroIntervention. 2009. PMID: 19527981 Clinical Trial.
823 results